Sutro Biopharma Inc
NASDAQ:STRO
STRO's latest stock split occurred on Dec 3, 2025
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, STRO traded at 0.7298 per share. Afterward, the share price was about 8.7.
The adjusted shares began trading on Dec 3, 2025. This was the only stock split in STRO's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Mar 20, 2026
|
S
|
Sonid Inc
KOSDAQ:060230
|
5-for-1
x5
|
1842 368.4 KRW | 478 478 KRW |
|
Mar 20, 2026
|
D
|
DELISTED SECURITIES
NYSE:IRE
|
1-for-4
/4
|
20.28 20.28 USD | 19.94 19.94 USD |
|
Mar 20, 2026
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
4-for-1
x4
|
1825 456.25 INR | 441.1 441.1 INR |
|
Mar 20, 2026
|
T
|
TJ Media Co Ltd
KOSDAQ:032540
|
3-for-2
x1.5
|
6170.0029 4113.3353 KRW | 4020 4020 KRW |
|
Mar 20, 2026
|
T
|
Tianci International Inc
OTC:CIIT
|
1-for-7
/7
|
0.27 1.89 USD | 1.72 1.72 USD |
METROPOLIS
Sutro Biopharma Inc
Glance View
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
